Picture the coordinator’s queue on a Monday morning: a stack of referrals from last week’s outreach push, an eligibility checklist that runs four pages, a sponsor portal that requires manual re-entry of data already sitting in the EMR, and a CRA who wants to know why screen failure rates are climbing. The coordinator has not yet opened her email. She already knows two of those referrals will not make it through the first gate, because they never do. The inefficiency is not invisible to her. She lives inside it every single day.

That experience now has a number attached to it. According to a survey reported by FierceBiotech, 59% of clinical trial sites report that fewer eligible patients are being recruited because of inefficiencies in their recruitment process. More than half. And the number that should stop every sponsor in their tracks: 52% of sites say at least one in five patient referrals are ruled ineligible before formal screening even begins. Those patients never touch an ICF. They consume coordinator hours, PI attention, and portal login minutes, and they disappear without ever entering the enrollment funnel.

Where the Funnel Actually Breaks

The instinct from the sponsor side is to read “recruitment inefficiency” as a patient supply problem. More outreach, more social media, broader geographic catchment. That diagnosis leads to more referrals flowing into the same broken workflow, which produces more pre-screen failures and more coordinator burnout, not more enrolled patients. The pipeline is not empty. The pipeline is leaking.

Protocol complexity is the upstream pressure most sponsors underweight. IQVIA’s 2026 analysis found that since 2005, procedure quantity has increased 139%, endpoints have risen 214%, and data collection requirements have surged 600%. Every one of those additions lands on the eligibility checklist. A coordinator running a complex oncology or metabolic disease protocol may spend anywhere from 30 to 60 minutes on a single eligibility determination for a patient who ultimately does not qualify, according to research on effort categories for cancer trial eligibility screening published in PMC. When a site is working five competing protocols simultaneously, that time arithmetic becomes a staffing crisis.

The site activation sequence compounds the problem. Sites that receive their eligibility criteria in final form less than two weeks before their SIV have not had time to socialize the inclusion and exclusion criteria with referring physicians, subspecialists, or even their own schedulers. A criterion that reads cleanly in the protocol synopsis lands differently when the intake coordinator is trying to explain to a patient why a creatinine value from three months ago, not two, disqualifies them. Pre-screening logs go uncompleted. Deviations accumulate. The TMF gains entries nobody wanted. And the sponsor’s enrollment curve stays flat while the CRA’s site visit report notes “coordinator reports difficulty identifying eligible patients.”

The cost of staying flat is not abstract. Tufts CSDD’s 2024 analysis puts the mean direct daily cost of a Phase II/III trial delay at approximately $40,000, and for Phase III specifically, the figure climbs higher. A site that loses four weeks to a correctable workflow problem is not a site problem. It is a $1.1 million problem, minimum, replicated across every underperforming site in the network.

The Activation Gap No SIV Closes

Here is the counterintuitive read on site readiness: a site that passes its SIV checklist is not a site that is ready to recruit. SIV confirms regulatory documents are in order, that the PI and coordinator have acknowledged the protocol, that IP storage and lab kits are staged. What SIV does not verify is whether the site’s internal patient identification workflow is calibrated to this protocol’s specific population. Those are different things, and the industry consistently treats them as the same thing.

Sites I work with across our network have described the same pattern in multiple therapeutic areas: the SIV goes cleanly, first-patient-in lands within the target window, and then the enrollment curve stalls at week six. When you pull the pre-screen log, the pattern is visible. Referrals are arriving from the right sources, but a single eligibility criterion, frequently a lab value threshold or a prior medication washout requirement, is disqualifying a disproportionate share of candidates. Nobody flagged it during protocol review because it did not look like an operational problem. It looked like a scientific decision.

That mismatch between scientific protocol design and operational site reality is precisely what ICH E6(R3) addresses in principle when it calls for sponsor oversight that accounts for site-specific context and workload. The guidance places explicit responsibility on sponsors to understand the operational environment of their sites, not just confirm their regulatory compliance. In practice, the oversight mechanism most commonly used is the monitoring visit report, which captures problems after they have already cost enrollment weeks.

ACRP’s 2024 trends analysis confirmed that 85% of clinical trials failed to recruit enough patients, with 80% delayed due to participant-related factors including geographic and logistical barriers. The sites already know about the logistical barriers. What the survey data now confirms is that the bottleneck exists inside the site’s own process, not just outside it in the patient population.

What Changes on Monday

For site teams, the lever is the pre-screening SOP, and most sites either do not have one or have one that has not been updated since the last protocol amendment. A working pre-screen SOP does three things: it defines who conducts the initial eligibility pass and what EMR fields they check, it assigns a maximum time threshold for that review before the case is escalated to the coordinator or PI, and it flags the top three to five disqualifying criteria by historical failure rate so the first five minutes of a referral review focus on the most likely exit points first. That last piece requires looking at your own site’s screen failure data, not the sponsor’s projected screen failure rate from the protocol synopsis, which is almost always optimistic.

For sponsors and CTMs, the operational fix is adding a pre-startup eligibility calibration call to the site activation sequence, positioned two to three weeks before SIV, not as a replacement for SIV but as a prerequisite to it. On that call, the site walks through its referral identification workflow against the actual inclusion and exclusion criteria, and the sponsor confirms which criteria have historically generated the highest screen failure rates in analogous trials. Fifteen minutes of that conversation before SIV is worth four weeks of enrollment recovery after it.

The sites are already telling sponsors what the problem is. Fifty-nine percent of them said it out loud in a survey. The operational question is whether the response will be another layer of outreach spend, or whether someone will finally sit down with the pre-screen log and do the arithmetic.

References

  1. FierceBiotech — “Over half of clinical trial sites see recruitment hindered by inefficiencies: survey”
  2. PR Newswire / myTomorrows — “myTomorrows Survey Reveals 52% of Clinical Trial Sites Say 1 in 5 Referrals Are Ineligible Before Screening Even Begins”
  3. IQVIA — “Assessing Protocol Complexity and Its Impact on Trial Outcomes”
  4. PMC / National Institutes of Health — “Effort categories for cancer clinical trial eligibility screening”
  5. Woodley Trial Solutions / Tufts CSDD — “How to Reduce Costly Delays in Clinical Trials”
  6. ACRP — “Enhancement, Efficiency, Equity, and Engagement: Four Trends Shaping Clinical Trials in 2024”
+ posts